Therapeutic strategies targeting cancer stem cells

Cancer Science

Volumn 107, Issue 1, 2016, Pages 5-11

  Yoshida, Go J ^a,b   Saya, Hideyuki ^c  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

CD44; Fbw7; Intratumoral heterogeneity; Niche; Plasticity

Indexed keywords

CYTOTOXIC AGENT;

CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STEM CELL; CELL CYCLE; CELL PLASTICITY; CELL SUBPOPULATION; GLIOMA STEM CELL; HUMAN; LIVER CANCER; MINIMAL RESIDUAL DISEASE; MOLECULARLY TARGETED THERAPY; OSTEOSARCOMA; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; DRUG EFFECTS; NEOPLASMS; PHYSIOLOGY;

ANIMALS; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84956579802     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12817     Document Type: Review

References (83)

1. Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 2013; 108: 479-85.
2. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-92.
3. Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer 2012; 12: 133-43.
4. Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell 2014; 54: 716-27.
5. Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-8.
6. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-7.
7. Jiang X, Gwye Y, Russell D et al. CD133 expression in chemo-resistant Ewing sarcoma cells. BMC Cancer 2010; 10: 116.
8. Kanwar SS, Yu Y, Nautiyal J, Patel BB, Majumdar AP. The Wnt/beta-catenin pathway regulates growth and maintenance of colonospheres. Mol Cancer 2010; 9: 212.
9. Sugihara E, Shimizu T, Kojima K et al. Ink4a and Arf are crucial factors in the determination of the cell of origin and the therapeutic sensitivity of Myc-induced mouse lymphoid tumor. Oncogene 2012; 31: 2849-61.
10. Charafe-Jauffret E, Ginestier C, Birnbaum D. Breast cancer stem cells: tools and models to rely on. BMC Cancer 2009; 9: 202.
11. Rocco A, Liguori E, Pirozzi G et al. CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumors. J Cell Physiol 2012; 227: 2686-93.
12. Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med 2005; 353: 811-22.
13. LaBarge MA, Bissell MJ. Is CD133 a marker of metastatic colon cancer stem cells? J Clin Investig 2008; 118: 2021-4.
14. Ishimoto T, Nagano O, Yae T et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011; 19: 387-400.
15. Wu Z, Wei D, Gao W et al. TPO-induced metabolic reprogramming drives liver metastasis of colorectal cancer CD110 + tumor-initiating cells. Cell Stem Cell 2015; 17: 47-59.
16. Maugeri-Sacca M, Bartucci M, De Maria R. DNA damage repair pathways in cancer stem cells. Mol Cancer Ther 2012; 11: 1627-36.
17. Skvortsov S, Debbage P, Lukas P, Skvortsova I. Crosstalk between DNA repair and cancer stem cell (CSC) associated intracellular pathways. Semin Cancer Biol 2015; 31: 36-42.
18. Ishimoto T, Oshima H, Oshima M et al. CD44 + slow-cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E2 in gastric tumorigenesis. Cancer Sci 2010; 101: 673-8.
19. Yoshida GJ, Saya H. EpCAM expression in the prostate cancer makes the difference in the response to growth factors. Biochem Biophys Res Commun 2014; 443: 239-45.
20. Weinberg R, Fisher DE, Rich J. Dynamic and transient cancer stem cells nurture melanoma. Nat Med 2010; 16: 758.
21. Shen YA, Wang CY, Hsieh YT, Chen YJ, Wei YH. Metabolic reprogramming orchestrates cancer stem cell properties in nasopharyngeal carcinoma. Cell Cycle 2015; 14: 86-98.
22. Saga I, Shibao S, Okubo J et al. Integrated analysis identifies different metabolic signatures for tumor-initiating cells in a murine glioblastoma model. Neuro-oncology 2014; 16: 1048-56.
23. Dean M. ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 2009; 14: 3-9.
24. Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009; 9: 665-74.
25. Creighton CJ, Li X, Landis M et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009; 106: 13820-5.
26. Viale A, Pettazzoni P, Lyssiotis CA et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 2014; 514: 628-32.
27. Kurtova AV, Xiao J, Mo Q et al. Blocking PGE-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature 2015; 517: 209-13.
28. Yoshida GJ, Fuchimoto Y, Osumi T et al. Li-Fraumeni syndrome with simultaneous osteosarcoma and liver cancer: increased expression of a CD44 variant isoform after chemotherapy. BMC Cancer 2012; 12: 444.
29. Sato T, van Es JH, Snippert HJ et al. Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature 2011; 469: 415-8.
30. Rabbani P, Takeo M, Chou W et al. Coordinated activation of Wnt in epithelial and melanocyte stem cells initiates pigmented hair regeneration. Cell 2011; 145: 941-55.
31. Guerrouahen BS, Al-Hijji I, Tabrizi AR. Osteoblastic and vascular endothelial niches, their control on normal hematopoietic stem cells, and their consequences on the development of leukemia. Stem Cells Int 2011; 2011: 375857.
32. De Veirman K, Rao L, De Bruyne E et al. Cancer associated fibroblasts and tumor growth: focus on multiple myeloma. Cancers 2014; 6: 1363-81.
33. Jinushi M, Baghdadi M, Chiba S, Yoshiyama H. Regulation of cancer stem cell activities by tumor-associated macrophages. Am J Cancer Res 2012; 2: 529-39.
34. Hoesel B, Schmid JA. The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer 2013; 12: 86.
35. Schepers AG, Snippert HJ, Stange DE et al. Lineage tracing reveals Lgr5 + stem cell activity in mouse intestinal adenomas. Science 2012; 337: 730-5.
36. Okamoto N, Aoto T, Uhara H et al. A melanocyte-melanoma precursor niche in sweat glands of volar skin. Pigment Cell Melanoma Res 2014; 27: 1039-50.
37. Calabrese C, Poppleton H, Kocak M et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11: 69-82.
38. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007; 129: 465-72.
39. Liang D, Ma Y, Liu J et al. The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells. BMC Cancer 2012; 12: 201.
40. Pietras A, Katz AM, Ekstrom EJ et al. Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell 2014; 14: 357-69.
41. Ribatti D, Mangialardi G, Vacca A. Stephen Paget and the 'seed and soil' theory of metastatic dissemination. Clin Exp Med 2006; 6: 145-9.
42. Shiozawa Y, Pedersen EA, Havens AM et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Investig 2011; 121: 1298-312.
43. Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 2005; 328: 679-87.
44. Sun YX, Schneider A, Jung Y et al. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 2005; 20: 318-29.
45. Norton L, Massague J. Is cancer a disease of self-seeding? Nat Med 2006; 12: 875-8.
46. Comen E, Norton L, Massague J. Clinical implications of cancer self-seeding. Nat Rev Clin Oncol 2011; 8: 369-77.
47. Kim MY, Oskarsson T, Acharyya S et al. Tumor self-seeding by circulating cancer cells. Cell 2009; 139: 1315-26.
48. Islam F, Qiao B, Smith RA, Gopalan V, Lam AK. Cancer stem cell: fundamental experimental pathological concepts and updates. Exp Mol Pathol 2015; 98: 184-91.
49. Csermely P, Hodsagi J, Korcsmaros T et al. Cancer stem cells display extremely large evolvability: alternating plastic and rigid networks as a potential mechanism: network models, novel therapeutic target strategies, and the contributions of hypoxia, inflammation and cellular senescence. Semin Cancer Biol 2015; 30: 42-51.
50. Harris JF, Best MW. Dynamic heterogeneity: metastatic variants to liver are generated spontaneously in mouse embryonal carcinoma cells. Clin Exp Metastasis 1988; 6: 451-62.
51. Roesch A, Fukunaga-Kalabis M, Schmidt EC et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010; 141: 583-94.
52. Roesch A, Vultur A, Bogeski I et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell 2013; 23: 811-25.
53. Davis H, Irshad S, Bansal M et al. Aberrant epithelial GREM1 expression initiates colonic tumorigenesis from cells outside the stem cell niche. Nat Med 2015; 21: 62-70.
54. Schwitalla S, Fingerle AA, Cammareri P et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 2013; 152: 25-38.
55. Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010; 17: 421-33.
56. Cicenas J, Valius M. The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol 2011; 137: 1409-18.
57. Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 2008; 8: 83-93.
58. Matsumoto A, Takeishi S, Kanie T et al. p57 is required for quiescence and maintenance of adult hematopoietic stem cells. Cell Stem Cell 2011; 9: 262-71.
59. Osuka S, Sampetrean O, Shimizu T et al. IGF1 receptor signaling regulates adaptive radioprotection in glioma stem cells. Stem Cells 2013; 31: 627-40.
60. Shimizu T, Sugihara E, Yamaguchi-Iwai S et al. IGF2 preserves osteosarcoma cell survival by creating an autophagic state of dormancy that protects cells against chemotherapeutic stress. Cancer Res 2014; 74: 6531-41.
61. Yada M, Hatakeyama S, Kamura T et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 2004; 23: 2116-25.
62. Cheng Y, Li G. Role of the ubiquitin ligase Fbw7 in cancer progression. Cancer Metastasis Rev 2012; 31: 75-87.
63. Yumimoto K, Akiyoshi S, Ueo H et al. F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous manner. J Clin Investig 2015; 125: 621-35.
64. Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 2007; 357: 258-65.
65. Takeishi S, Matsumoto A, Onoyama I, Naka K, Hirao A, Nakayama KI. Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. Cancer Cell 2013; 23: 347-61.
66. Yoshida GJ, Saya H. Inversed relationship between CD44 variant and c-Myc due to oxidative stress-induced canonical Wnt activation. Biochem Biophys Res Commun 2014; 443: 622-7.
67. Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. Mol Pathol 1999; 52: 189-96.
68. Prince ME, Sivanandan R, Kaczorowski A et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007; 104: 973-8.
69. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-51.
70. Lynch KW. Consequences of regulated pre-mRNA splicing in the immune system. Nat Rev Immunol 2004; 4: 931-40.
71. Tanabe KK, Ellis LM, Saya H. Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet 1993; 341: 725-6.
72. Marzese DM, Liu M, Huynh JL et al. Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome. Pigment Cell Melanoma Res 2015; 28: 82-93.
73. Horiguchi K, Sakamoto K, Koinuma D et al. TGF-beta drives epithelial-mesenchymal transition through deltaEF1-mediated downregulation of ESRP. Oncogene 2012; 31: 3190-201.
74. Saint-Andre V, Batsche E, Rachez C, Muchardt C. Histone H3 lysine 9 trimethylation and HP1gamma favor inclusion of alternative exons. Nat Struct Mol Biol 2011; 18: 337-44.
75. Olsson E, Honeth G, Bendahl PO et al. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer 2011; 11: 418.
76. Yoshida GJ, Saya H, Zouboulis CC. Three-dimensional culture of sebaceous gland cells revealing the role of prostaglandin E2-induced activation of canonical Wnt signaling. Biochem Biophys Res Commun 2013; 438: 640-6.
77. Bassi MT, Gasol E, Manzoni M et al. Identification and characterisation of human xCT that co-expresses, with 4F2 heavy chain, the amino acid transport activity system xc. Pflugers Arch 2001; 442: 286-96.
78. Ito K, Hirao A, Arai F et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med 2006; 12: 446-51.
79. Yae T, Tsuchihashi K, Ishimoto T et al. Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat Commun 2012; 3: 883.
80. Tavanez JP, Valcarcel J. A splicing mastermind for EMT. EMBO J 2010; 29: 3217-8.
81. Plosker GL, Croom KF. Sulfasalazine: a review of its use in the management of rheumatoid arthritis. Drugs 2005; 65: 1825-49.
82. Harris IS, Treloar AE, Inoue S et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell 2015; 27: 211-22.
83. Yoshikawa M, Tsuchihashi K, Ishimoto T et al. xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. Cancer Res 2013; 73: 1855-66.